TY - JOUR
T1 - Etoposide in combination as first‐line chemotherapy for advanced Hodgkin disease. A cancer and leukemia group B study
AU - Kirshner, Jeffrey J.
AU - Anderson, James R.
AU - Parker, Barbara
AU - Barcos, Maurice
AU - Cooper, M. Robert
AU - Burns, Linda J.
AU - Peterson, Bruce A.
AU - Gottlieb, Arlan J.
PY - 1993/3/1
Y1 - 1993/3/1
N2 - Background. In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease. Methods. Thirty‐six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophosphamide (MOPLEC), and then treated with five to seven additional courses of a known “curative” regimen: nitrogen mustard, vinblastine, prednisone, and procarbazine (MVPP). Results. After treatment with MOPLEC, there were 16 complete responders (44%) and 18 partial responders (50%). One patient had progressive disease and one patient was taken off study after an anaphylactic reaction to etoposide. After completing the entire protocol, 32 patients achieved complete remission (CR) (89%) and 3 achieved partial remission (PR) (8%). Five CR patients have relapsed and three additional patients have died in CR without recurrence. At 36 months, the estimated failure‐free survival is 61% and overall survival is 72%. Conclusions. This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease.
AB - Background. In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease. Methods. Thirty‐six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophosphamide (MOPLEC), and then treated with five to seven additional courses of a known “curative” regimen: nitrogen mustard, vinblastine, prednisone, and procarbazine (MVPP). Results. After treatment with MOPLEC, there were 16 complete responders (44%) and 18 partial responders (50%). One patient had progressive disease and one patient was taken off study after an anaphylactic reaction to etoposide. After completing the entire protocol, 32 patients achieved complete remission (CR) (89%) and 3 achieved partial remission (PR) (8%). Five CR patients have relapsed and three additional patients have died in CR without recurrence. At 36 months, the estimated failure‐free survival is 61% and overall survival is 72%. Conclusions. This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease.
KW - Hodgkin disease
KW - chemotherapy
KW - etoposide
KW - pilot study
UR - http://www.scopus.com/inward/record.url?scp=0027510633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027510633&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19930301)71:5<1852::AID-CNCR2820710523>3.0.CO;2-T
DO - 10.1002/1097-0142(19930301)71:5<1852::AID-CNCR2820710523>3.0.CO;2-T
M3 - Article
C2 - 8448749
AN - SCOPUS:0027510633
SN - 0008-543X
VL - 71
SP - 1852
EP - 1856
JO - Cancer
JF - Cancer
IS - 5
ER -
